Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

Sponsor
Chang Gung Memorial Hospital
Study ID
NCT06111443
Phase
PHASE2/PHASE3
Status
Active Not Recruiting

Conditions

  • Atrial Fibrillation Recurrent
  • Catheter Ablation

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical trial is to test the effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation. The main questions it aims to answer are: • If Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias \[atrial fibrillation (AF), atrial flutter (AFL) and atrial tachycardia (AT)\] greater than 30 seconds during one-year follow-up after catheter ablation. Participants will receive Dapagliflozin (FORXIGA) 10 milligram (mg) once a day (QD) for 3 months after catheter ablation of atrial fibrillation. Researchers will compare patients who receive usual care to see if Dapagliflozin will reduce the recurrence of all atrial tachyarrhythmias (AF/AFL/AT) during one-year follow-up after catheter ablation.

Key Dates

Start date
Dec 1, 2023
Status verified
Aug 2023
Primary completion
Nov 30, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
196 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin
    Dapagliflozin (FORXIGA) 10 mg QD for 3 months
  • No Intervention: Usual care
    guideline-direct usual care

Primary Outcome Measure

Freedom from all atrial tachyarrhythmias (AF/AFL/AT) [ Time Frame: 3,6 and 12 months after ablation ]